• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Cancer Vaccine Win Could Be A Turning Point For Moderna Stock (MRNA)

    Simply Wall St·11/01/2026 03:47:19
    Listen to the news
    • Merck and Moderna reported detailed Phase 3 INTerpath-001 data showing intismeran autogene plus KEYTRUDA cut recurrence or death risk by 42% and distant metastasis or death risk by 38% in high risk melanoma after surgery, with results presented at ESMO 2026 and accepted by The New England Journal of Medicine.
    • The therapy’s one patient at a time manufacturing model, which requires bespoke mRNA design based on each tumour’s DNA, raises real execution questions on cost, scale and turnaround time, at the same time that Moderna is working to turn oncology into a meaningful revenue pillar beyond respiratory vaccines.
    • This analysis will examine how Moderna’s investment narrative is being shaped by Phase 3 melanoma results that rely on complex individualized manufacturing at scale.
    Seize this moment in Moderna’s cancer story to review a hand picked group of oncology focused peers with resilient balance sheets through the list of solid balance sheet and fundamentals (24 results).

    Moderna Investment Narrative Recap

    To own Moderna, you need to believe the mRNA platform can evolve from a COVID heavy story into a broader vaccines, oncology and rare disease portfolio that eventually supports the current rich P/S multiple. The Phase 3 intismeran melanoma win supports that narrative, although the bespoke manufacturing model keeps execution risk front and center.

    In the near term, the key swing factor is how quickly Moderna can convert its pipeline and respiratory launches into steadier revenue while it is still reporting losses. The biggest operational risk is whether individualized oncology manufacturing can be run at scale without eroding margins, particularly with earnings expected to remain under pressure.

    The INTerpath 001 melanoma update is the announcement that matters most here because it directly tests Moderna’s bet on personalized mRNA oncology. Strong RFS and DMFS data, selection for an ESMO Presidential Symposium, and NEJM acceptance give the program medical credibility that supports the broader cancer thesis around intismeran.

    For you as a shareholder, the work now shifts to operations. Tumor sampling, rapid bespoke mRNA design and reliable production for each patient all need tight execution to move from trial batches to real world volume. That operational test, more than the headline efficacy numbers, feeds into the next leg of catalysts and risk around Moderna’s oncology ambitions.

    Moderna's current consensus story points to US$4.5b in revenue and US$721.6m in earnings by 2029, tied to an assumed 26.7% yearly revenue growth rate and a move from today’s earnings loss of about US$3.2b to that positive earnings figure. This represents roughly a US$3.9b swing in profit needed to close the gap.

    Uncover why Moderna's fair value indicates a 39% potential downside to its current price, suggesting that this premium may not hold.

    NasdaqGS:MRNA 1-Year Stock Price Chart
    NasdaqGS:MRNA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate story puts less weight on melanoma success and more on the risk that Moderna’s broader mRNA portfolio underdelivers. Those bearish analysts were only pencilling in about US$2.6b of revenue and US$451.8m of earnings by 2029 before this trial update. That is a far more cautious view. Use it as a reference point to compare several different forecasts and decide which assumptions feel closer to your own.

    Explore 4 other Moderna fair value estimates, including one that suggests as much as 56% downside from the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.

    Looking for more investment ideas beyond Moderna?

    If the Moderna story has sharpened your thinking but you want fresh opportunities, you can apply that same mindset to a wider universe of businesses with stronger balance sheets, different risk profiles and varied income potential.

    • For investors hunting for mispriced quality, scan a curated set of resilient companies trading below what fundamentals suggest through the 30 high quality undervalued stocks.
    • If capital preservation matters as much as upside, focus on businesses with steadier finances and cleaner leverage profiles using the 29 resilient stocks with low risk scores.
    • Income focused portfolios can cast a wider net by reviewing companies with higher yields that still show robust fundamentals through the 5 dividend fortresses.